Stockscreener 앱 받기
60.56
0.35%
-0.21
시간 외 거래:
60.65
0.09
+0.15%
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon (XENE) Today: Ends Down by 4.16% at $59.73 for the Current Session; Technical Setup: Support at $56.74 and Resistance at $62.72 Frame the Range under the Current SnapshotMcClellan Oscillator - Vinanet
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript - AOL.com
Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors? - simplywall.st
Xenon Pharmaceuticals (XENE) Holds Steady at $62.36 as Shares Consolidate Below Key ResistanceIV Rank - vinanet.vn
TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds - Sahm
Xenon Pharmaceuticals (XENE) Pulls Back 2.93% as Shares Approach Critical SupportCall Wall - vinanet.vn
Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding - simplywall.st
Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct - GuruFocus
(XENE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells 10,000 Shares of Stock - MarketBeat
Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64 - Stock Titan
Xenon Pharmaceuticals Insider Sold Shares Worth $640,550, According to a Recent SEC Filing - marketscreener.com
Xenon Pharmaceuticals Director Sold Shares Worth Over $640K - TradingView
Seller for XENE (NASDAQ: XENE) plans 10,000-share common stock sale - Stock Titan
Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Presents High-Quality Technical Breakout Setup - ChartMill
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity (XENE) - Seeking Alpha
HC Wainwright Issues Positive Outlook for XENE Earnings - MarketBeat
Xenon Pharmaceuticals Inc. (XENE): Analyst Consensus Highlights 26.65% Potential Upside - DirectorsTalk Interviews
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Brokers Issue Forecasts for XENE Q1 Earnings - MarketBeat
Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE) - webull.com
Xenon Pharmaceuticals Stock Price Forecast. Should You Buy XENE? - StockInvest.us
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $81 to $90 - Moomoo
H.C. Wainwright Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $74 - Moomoo
XENE Maintained by RBC Capital -- Price Target Lowered to $81.00 - GuruFocus
Xenon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Wedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating - Moomoo
Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says - marketscreener.com
Xenon Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $81.21, Implies 26% Upside - TradingView
FMR LLC (XENE) discloses 9.96M-share, 10.3% holding in Xenon Pharmaceuticals - Stock Titan
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus - Yahoo Finance
RBC Adjusts Xenon Pharmaceuticals PT to $81 From $82, Maintains Outperform Speculative Risk Rating - marketscreener.com
Xenon Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results - MarketBeat
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ... - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlig - GuruFocus
XENON PHARMACEUTICALS INC. : WEDBUSH RAISES TARGET PRICE TO $71 FROM $63 - Bitget
XENE Advances Pipeline with NDA Submission Plans Amid High Price-to-Sales Valuation - GuruFocus
Xenon Pharmaceuticals Q2 Loss Widens - marketscreener.com
Earnings Flash (XENE) Xenon Posts Q2 Loss Per Share $1.11, vs. FactSet Est of $1.14 Loss - marketscreener.com
Xenon Pharmaceuticals Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Xenon Pharmaceuticals Inc. Q2 2026: Revenue $0 EPS $(1.11) — 10-Q Summary - TradingView
Xenon Pharmaceuticals Inc. R (XP0.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Earnings Flash (XENE) Xenon Pharmaceuticals Inc. Reports Q2 Revenue $0 - marketscreener.com
XENE: Azetukalner NDA on track for Q3 2026; strong cash position supports ongoing late-stage trials - TradingView
Xenon Reports Q2 2026 Financial Results and Provides Business Update - The Manila Times
BRIEF-Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million - TradingView
Xenon Pharmaceuticals earnings on deck as FDA approval push nears By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals earnings on deck as FDA approval push nears - Investing.com
FMR LLC and Abigail Johnson report 9.9% Xenon Pharmaceuticals (XENE) holding - Stock Titan
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ... By GuruFocus - Investing.com Canada
XENE Q2'26 Earnings: EPS estimate is (1.14) USD - TradingView
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: A Promising 29.99% Upside In Biotech Innovation - DirectorsTalk Interviews
Xenon Pharmaceuticals Inc. $XENE Shares Bought by Sei Investments Co. - MarketBeat
0.00%
3.22%
자본화:
|
볼륨(24시간):